Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Advanced Liver Cancers 1

Interventions

Cisplatin 4Cetuximab 4pembrolizumab 3Radiotherapy 3cemiplimab 2Surveys and Questionnaires 2Magnetic Resonance Spectroscopy 2Carboplatin 2olaparib 1niraparib 1fludarabine 1dostarlimab 1calcipotriene 1avelumab 1atezolizumab 1alpha-2'-deoxythioguanosine 1aldesleukin 1Watchful Waiting 1Tiragolumab 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiosurgery 1Platinum 1Phlebotomy 1Paclitaxel 1Nivolumab 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Tiragolumab × 30 days × Clear all
NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡